Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Galectin Therapeutics Names Jack Callicutt CFO - Quick Facts

RELATED NEWS
Trade GALT now with 

Galectin Therapeutics (GALT: Quote), the developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the appointment of Jack Callicutt to the position of Chief Financial Officer, effective July 1, 2013.

Callicutt will lead the Company's financial activities, including financial reporting, accounting, risk management, public company governance, interaction with capital markets, and public and investor relations.

Callicutt has over 22 years of public and private company experience including more than a decade of audit, tax, and SEC registrant experience with a major accounting firm. He was most recently CFO for REACH Health, Inc., a telemedicine firm, where he completed a $4 million private placement.

Previous positions include CFO of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 million in financing. Previous experiences also include CFO roles at private companies including IVOX and Tikvah Therapeutics, and at Coratus Genetics, a publicly traded biopharmaceutical company.

Register
To receive FREE breaking news email alerts for GALECTIN THERAPEUTICS INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.